Evidence map›Paper›PMID 26041764›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2015

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

S Gillessen, A Omlin, G Attard, J S de Bono, E Efstathiou, K Fizazi, S Halabi, P S Nelson, O Sartor, M R Smith and 34 more

Registry-linked trialAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04225910 (Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer), which is not on this map. Cited by 125 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04225910 early_phase1unknown statusnot on this mapstarted 2020, after this paper: background citation

Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer

TypeinterventionalSponsorXinhua Hospital, Shanghai Jiao Tong University School of MedicineRan2020 to 2021Enrolled20ConditionsMetastatic Castration-resistant Prostate CancerArms225Ac-PSMA
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Guideline
  6. Pooled it
  7. Trial
  8. BaselineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Trial
  14. TheEuropean journal of nuclear medicine and molecular imaging · 2017
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Management of bone health in cancer survivorship: a systematic review of clinical guidelines.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

44 authors.

S GillessenDepartment of Oncology/Haematology, Kantonsspital St Gallen, St Gallen, Switzerland silke.gillessen@kssg.ch.
A OmlinDepartment of Oncology/Haematology, Kantonsspital St Gallen, St Gallen, Switzerland.
G AttardProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
J S de BonoProstate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
E EfstathiouDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston Department of Genitourinary Medical Oncology, David H. Koch Centre, The University of Texas M. D. Anderson Cancer Centre, Houston, USA Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
K FizaziDepartment of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
S HalabiDepartment of Biostatistics and Bioinformatics, Duke University, Durham.
P S NelsonDivision of Human Biology, Fred Hutchinson Cancer Research Centre, Seattle.
O SartorTulane Cancer Centre, Tulane University, New Orleans.
M R SmithMassachusetts General Hospital Cancer Centre, Boston.
H R SouleProstate Cancer Foundation, Santa Monica, USA.
H AkazaResearch Centre for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
T M BeerOregon Health & Science University Knight Cancer Institute, Portland.
H BeltranDepartment of Medicine, Weill Cornell Medical College, New York.
A M ChinnaiyanMichigan Centre for Translational Pathology, Department of Pathology Department of Urology, Comprehensive Cancer Centre Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, USA.
G DaugaardDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
I D DavisMonash University and Eastern Health, Eastern Health Clinical School, Box Hill, Australia.
M De SantisCancer Research Centre, University of Warwick, Warwick, UK Ludwig Boltzmann Institute for Applied Cancer Research, Kaiser Franz Josef-Spital, Vienna, Austria.
C G DrakeJohns Hopkins Sidney Kimmel Cancer Center and The Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, USA.
R A EelesThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
S FantiDepartment of Nuclear Medicine, Policlinico S. Orsola, University of Bologna, Bologna, Italy.
M E GleaveUrological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
A HeidenreichKlinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany.
M HussainUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, USA.
N D JamesCancer Research Centre, University of Warwick, Warwick, UK Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, Birmingham, UK.
F E LecouvetDepartment of Radiology, Centre du Cancer et Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Brussels, Belgium.
C J LogothetisDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston Department of Genitourinary Medical Oncology, David H. Koch Centre, The University of Texas M. D. Anderson Cancer Centre, Houston, USA.
K MastrisEuropa Uomo Prostate Patients, Clayhall Ilford, UK.
S NilssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
W K OhDivision of Haematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
D OlmosProstate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
A R PadhaniPaul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood.
C ParkerProstate Cancer Targeted Therapy Group, Academic Urology Unit and Department of Diagnostic Radiology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
M A RubinInstitute for Precision Medicine, Meyer Cancer Center, Department of Pathology and Urology, Weill Cornell Medical College and NewYork Presbyterian, New York, USA.
J A SchalkenDepartment of Urology, Radboud University, Medical Centre, Nijmegen, The Netherlands.
H I ScherDepartment of Medicine, Weill Cornell Medical College, New York Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York.
A SellaDepartment of Oncology, Assaf Harofeh Medical Centre, Tel-Aviv University, Sackler School of Medicine, Zerifin, Israel.
N D ShoreDepartment of Urology, Carolina Urologic Research Centre, Myrtle Beach.
E J SmallHelen Diller Family Comprehensive Cancer Centre, UCSF, San Francisco, USA.
C N SternbergDepartment of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.
H SuzukiDepartment of Urology, Toho University Sakura Medical Center, Chiba, Japan.
C J SweeneyDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
I F TannockDepartment of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Canada.
B TombalService D'Urologie, Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium.

Funding

Midcareer Investigator AwardK24CA121990 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SMITH, MATTHEW RAYMOND · 2007 to 2016
$1.9M
Cancer Research UK 13239Cancer Research UK 15007Cancer Research UK 17528NCI NIH HHS K24 CA121990Prostate Cancer UK PG12-49
6 · The paper itself

Abstract

The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

Indexed as

AdenocarcinomaAndrogen AntagonistsAntineoplastic AgentsAntineoplastic Agents, HormonalBone Density Conservation AgentsDocetaxelHumansMaleOrchiectomyPractice Guidelines as TopicProstatectomyProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantRadiotherapy, AdjuvantTaxoidsAndrogen AntagonistsAntineoplastic AgentsAntineoplastic Agents, HormonalBone Density Conservation AgentsDocetaxelTaxoidsadvanced prostate cancercastration-naïve prostate cancercastration-resistant prostate cancerconsensustherapeutics

Identifiers

PMID26041764
PMCPMC4511225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.